3-fluoro-piperidines as NMDA/NR2B antagonists

Details for Australian Patent Application No. 2004245522 (hide)

Owner Merck & Co., Inc.

Inventors McCauley, John A.; Claiborne, Christopher F.; Claremon, David A.; Liverton, Nigel J.

Agent Spruson & Ferguson

Pub. Number AU-B-2004245522

PCT Pub. Number WO2004/108705

Priority 60/475,938 04.06.03 US

Filing date 28 May 2004

Wipo publication date 16 December 2004

Acceptance publication date 29 October 2009

International Classifications

C07D 401/12 (2006.01) Heterocyclic compounds containing two or more hetero rings

A61K 31/506 (2006.01) - not condensed and containing further heterocyclic rings

A61P 25/16 (2006.01) Drugs for disorders of the nervous system

C07D 417/12 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group

Event Publications

8 December 2005 PCT application entered the National Phase

  PCT publication WO2004/108705 Priority application(s): WO2004/108705

29 October 2009 Application Accepted

  Published as AU-B-2004245522

28 January 2010 Alteration of Name

  The name of the applicant has been altered to Merck Sharp & Dohme Corp.

25 February 2010 Standard Patent Sealed

11 October 2012 Alteration of Name

  The name of the patentee has been altered to Merck Sharp & Dohme Corp.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004245525-Silicone based flame retardant systems for textiles

2004245514-Connective tissue growth factor antibodies